Back to News
Market Impact: 0.3
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
Source: reuters.com
IPOs & SPACsHealthcare & BiotechPrivate Markets & Venture
Iambic Therapeutics, a drug developer backed by Nvidia and Qatar's sovereign wealth fund, filed for a U.S. IPO on Monday. The filing adds to an active fall biotech-listing pipeline and signals continued investor appetite for venture-backed life-sciences issuers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
NVDA0.10
More News
- Microsoft declines option to expand Texas data center deal with Nscale, source says
- Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom